Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
CDK4/6 inhibitors after progression on a CDK4/6 inhibitor
12 evidence topics · 12 sources
Guideline recommendation: NCCN, another CDK4/6 inhibitor after progression
Guideline recommendation: ABC8, CDK4/6 inhibition beyond progression
“In view of the modest absolute benefit, the suboptimal control arm, and the availability of multiple biomarker-driven options in the post-CDK4/6i setting, the panel considers continued CDK4/6i beyond progression a less preferred strategy, reserving it for patients without access to other targeted therapies and in whom prior CDK4/6i benefit exceeded 12 months; when used, both the CDK4/6i and the endocrine agent should be changed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline recommendation: ASCO 2021, fulvestrant plus a CDK4/6 inhibitor
“Fulvestrant and a CDK4/6 inhibitor should be offered to patients with progressive disease during treatment with AIs (or who develop a recurrence within 1 year of adjuvant AI therapy) with or without one line of prior chemotherapy for metastatic disease, or as first-line therapy. Treatment should be limited to those without prior exposure to CDK4/6 inhibitors in the metastatic setting (type: evidence-based, benefits outweigh harms; evidence quality: high; strength of recommendation: strong).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Abemaciclib plus fulvestrant, postMONARCH: progression-free survival
“At the primary analysis (258 events), the hazard ratio (HR) was 0.73 (95% CI, 0.57 to 0.95; nominal P = .017), with median PFS 6.0 (95% CI, 5.6 to 8.6) versus 5.3 (95% CI, 3.7 to 5.6) months and 6-month PFS rates of 50% and 37% in the abemaciclib + fulvestrant and placebo + fulvestrant arms, respectively. These results were supported by BICR-assessed PFS (HR, 0.55 [95% CI, 0.39 to 0.77]; nominal P < .001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with measurable disease, investigator-assessed ORR was improved with abemaciclib + fulvestrant versus placebo + fulvestrant (17% v 7%; nominal P = .015).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Abemaciclib plus fulvestrant, postMONARCH: overall survival
“Median OS was 32.1 months with abemaciclib plus fulvestrant versus 24.6 months with placebo plus fulvestrant (HR 0.80, 95% CI 0.60-1.06, P = 0.11, boundary for significance not reached).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Updated PFS was consistent with the primary analysis (HR 0.78, 95% CI 0.62-0.99, nominal P = 0.039).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ribociclib with switched endocrine therapy, MAINTAIN
“Of the 119 randomly assigned participants, 103 (86.5%) previously received palbociclib and 14 participants received ribociclib (11.7%). There was a statistically significant PFS improvement for patients randomly assigned to switched ET plus ribociclib (median, 5.29 months; 95% CI, 3.02 to 8.12 months) versus switched ET plus placebo (median, 2.76 months; 95% CI, 2.66 to 3.25 months) HR, 0.57 (95% CI, 0.39 to 0.85); P = .006.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 6 and 12 months, the PFS rate was 41.2% and 24.6% with ribociclib, respectively, compared with 23.9% and 7.4% with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Palbociclib continued with fulvestrant, PACE
“Palbociclib was the most common previous CDK4/6i (90.9%). The median PFS was 4.8 months on F and 4.6 months on F + P (hazard ratio [HR], 1.11 [90% CI, 0.79 to 1.55]; P = .62).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Imlunestrant plus abemaciclib, EMBER-3: combination arm
“Among 426 patients in the comparison of imlunestrant–abemaciclib with imlunestrant, the median progression-free survival was 9.4 months and 5.5 months, respectively (hazard ratio, 0.57; 95% CI, 0.44 to 0.73; P<0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, most patients (65%) in the imlunestrant–abemaciclib group in our trial had received a CDK4/6 inhibitor previously, and the treatment effect of imlunestrant–abemaciclib (hazard ratio for progression or death, 0.51) in these patients was consistent with that in the overall population, and the median progression-free survival was 9.1 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Imlunestrant plus abemaciclib, EMBER-3: ESR1-mutated subgroup in the approval
Imlunestrant plus abemaciclib: NCCN subgroup with prior CDK4/6 inhibitor
Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib: indirect treatment comparison
“Though not powered for formal hypothesis testing, PFS favored imlunestrant + abemaciclib versus fulvestrant + abemaciclib across all three ITC methods. Hazard ratios (95% confidence intervals) for Bucher, MAIC, and PSM were 0.77 (0.58-1.04), 0.77 (0.55-1.06), and 0.83 (0.56-1.22), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote